Lumos Diagnostics (ASX:LDX) Secures Additional Medicare Coverage
Lumos Diagnostics (ASX:LDX) expands Medicare reimbursement for FebriDx to over 55% of US coverage, enhancing market access.
Category: Healthcare
Telix Pharmaceuticals Limited (ASX:TLX) Reports $186M Q1 Revenue
Telix Pharmaceuticals Limited (ASX:TLX) reports a 62% increase in Q1 2025 revenue, reaching $186M.
Clarity Pharmaceuticals (ASX:CU6) Signs Copper-64 Supply Agreement with Nusano
Clarity Pharmaceuticals (ASX:CU6) secures a copper-64 supply agreement with Nusano to support clinical trials and commercialization.
Anatara Lifesciences (ASX:ANR) Announces Phase II GaRP-IBS Trial Results
Anatara Lifesciences (ASX:ANR) reports Phase II GaRP-IBS trial results, highlighting safety and significant improvements in anxiety scores.
Imricor Medical Systems (ASX:IMR) Receives CE Mark Approval for Advantage-MR System
Imricor Medical Systems (ASX:IMR) secures CE Mark approval for its Advantage-MR system under the new EU Medical Device Regulation, anticipating EU launch in June.
PainChek Ltd (ASX:PCK) Secures $1.41M R&D Tax Refund, Advances FDA Review, and Launches Infant App
PainChek Ltd (ASX:PCK) secures a $1.41m R&D tax refund, advances FDA review for its Adult App, and launches the Infant App on Apple App Store.
4DMedical Limited (ASX:4DX) Lodges Supplementary Prospectus
4DMedical Limited (ASX:4DX) lodges a supplementary prospectus amending the terms of its New and Piggyback Options offers.
Pro Medicus Limited (ASX:PME) Signs Multi-Year Research Collaboration with UCSF
Pro Medicus Limited (ASX:PME) enters a multi-year AI research collaboration with UCSF to advance healthcare imaging solutions.
EBR Systems (ASX:EBR) Secures NTAP Reimbursement Approval
EBR Systems (ASX:EBR) proposes CMS approval of NTAP reimbursement for its WiSE CRT System, advancing US market strategy.
Clarity Pharmaceuticals (ASX:CU6) Treats First Patient in Phase II SECuRE Trial
Clarity Pharmaceuticals (ASX:CU6) begins Phase II SECuRE trial with first patient treated and enhances 67Cu-SAR-bisPSMA formulation.